ST. JOHN'S, NL / ACCESSWIRE / August 24, 2020 / Sokoman Minerals Corp. (TSXV:SIC)(OTCQB:SICNF) (the "Company" or "Sokoman") is pleased to announce that it has received the necessary permits to start Phase 6 diamond drilling at the Moosehead Gold Project in Central Newfoundland and is expecting the first drill on site shortly after the Labour Day weekend.

Moosehead Project

The 100%-owned Moosehead Gold Project is located along the Trans-Canada Highway in North Central Newfoundland, on the same trend as the advanced Valentine Lake Project (Marathon Gold), and proximal to New Found Gold's Queensway Project. Both the Moosehead and Queensway projects are targeting high-grade, turbidite hosted, Fosterville-type gold mineralization.

Since acquiring the project in 2018 and discovering the Eastern Trend mineralization in the first hole, the Company has intersected outstanding drill results in the Eastern Trend in all 5 drill phases completed. Highlights* from each of the 5 phases include:

Phase 1

MH-18-01

11.90 m @ 44.96 g/t Au, incl. 5.65 m @ 93.56 g/t Au

Phase 2

MH-18-39

5.10 m @ 124.20 g/t Au, incl. 1.10 m @ 550.30 g/t Au

Phase 3

MH-19-62

7.20 m @ 22.35 g/t Au, incl. 4.80 m @ 33.59 g/t Au

Phase 4

MH-19-81

6.40 m @ 17.34 g/t Au, incl. 1.45 m @ 75.50 g/t Au

Phase 5

MH-20-86

5.20 m @ 16.85 g/t Au, incl. 1.35 m @ 61.11 g/t Au

*Reported lengths are core lengths believed to be 70% – 90% of true thicknesses.

The mineralization has been defined over a 500 m strike length and to 200 m vertical depth and remains open for expansion along strike and to depth.

Tim Froude, President and CEO of Sokoman, states: "Now that all of the permits have been received, we can mobilize our crew and start site preparations for the largest drill program to date at Moosehead. The 10,000 m program will start with one drill targeting the strike extent of the lower main zone, where our previous drill programs have returned some of the highest-grade intersections in the district, including 4.80 m @ 33.59 g/t Au (MH-19-62) and 6.40 m @ 17.34 g/t Au (MH-19-81) at depths less than 200 m vertically. The zone is open to depth and along strike. A second drill will focus on extending the gold mineralization to depth with a series of holes testing to at least the 400 m vertical level. In addition, we will be testing newly defined targets such as the South Pond area where recent prospecting located high-grade quartz boulders with values up to 157 g/t Au (July 30, 2020 Sokoman Minerals Corp. News Release) that closely resemble the high-grade Eastern Trend mineralization located 400 m to the north."

The Company has merged C-horizon till sampling data with the winter heli-mag survey to define targets for drill testing, including tills with up to 54 gold grains with 34 delicate / modified grains, indicating proximity to the source, 1 km to the southwest, up-ice of the Eastern Trend in an area with no previous drilling.

COVID-19 Update

To ensure a working environment that protects the health and safety of the staff and contractors, Sokoman is operating under federally and provincially mandated and recommended guidelines during the current COVID-19 alert level.

About Sokoman Minerals Corp.

Sokoman Minerals Corp. is a discovery-oriented company with projects in Newfoundland & Labrador, Canada. The Company's primary focus is its portfolio of gold projects (Moosehead, Crippleback Lake and East Alder) in Central Newfoundland on the structural corridor hosting *Marathon Gold's Valentine Lake project that has estimated proven mineral reserves of 1.3 million ounces (26.3 million tonnes at 1.52 grams per tonne) and probable mineral reserves of 600,000 oz (14.8 million t at 1.23 g/t). Total measured plus indicated resources (inclusive of the mineral reserves) comprise 3.06 million ounces (54.9 million t @ 1.75 g/t). Additional inferred mineral resources are 960,000 oz (16.77 million t at 1.78 g/t Au).

Sokoman also has a 100% interest in an early-stage antimony/gold project in Newfoundland recently optioned to White Metal Resources Inc. In Labrador, the Company has a 100% interest in the Iron Horse (Fe) project.

*Mineralization hosted on adjacent and/or nearby properties is not necessarily indicative of mineralization hosted on the Company's property.

The Company would like to thank the Government of Newfoundland and Labrador for financial support of the project through the Junior Exploration Assistance Program. Sokoman has also applied for funding for the 2020 season.

To learn more, please contact:

Timothy Froude, P. Geo.,
President & CEO
709-765-1726
tim@sokomanmineralscorp.com

Cathy Hume, Director, Investor Relations
416-868-1079 x231
cathy@chfir.com

Website: www.sokomanmineralscorp.com
Twitter: @SokomanMinerals
Facebook: @SokomanMinerals

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Investors are cautioned that trading in the securities of the Corporation should be considered highly speculative. Except for historical information contained herein, this news release contains forward- looking statements that involve risks and uncertainties. Actual results may differ materially. Sokoman Minerals Corp. will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Sokoman Minerals Corp.

SOURCE: Sokoman Minerals Corp.

ReleaseID: 602815

VANCOUVER, BC / ACCESSWIRE / August 24, 2020 / CIBT Education Group Inc. (TSX:MBA)(OTCQX:MBAIF) ("CIBT" or the "Company") is pleased to announce the commencement of a review process to explore opportunities to enhance shareholder value.

The objective of this undertaking is to evaluate opportunities to unlock the value of its wholly-owned education-real estate subsidiary, Global Education City Holdings Inc. ("Global Holdings"), by potentially spinning it off as a separately listed entity on a recognized North American stock exchange while seeking strategic funding opportunities globally.

To assist with the review, CIBT has retained advisors in the United States, Asia and elsewhere to assist it with identifying a value-enhancing transaction for Global Holdings.

CIBT is uniquely positioned as a leader in the Canadian education and student housing sectors. Since beginning the student housing division in 2015, the portfolio of assets held by various limited partnerships controlled by CIBT has grown to a total of ten GEC® branded properties that are currently operational or under construction. As of May 31st, 2020, the market value of the GEC® portfolio appraised by third-party valuators was approximately C$580M. Further, the portfolio value (including development budgets) exceeds approximately C$1.4 billion.

"As a publically traded company, our objective has always been to increase the value of our company by continuing to drive growth and assess our underlying business for value-enhancing alternatives," said Toby Chu, Chairman and CEO of CIBT. "Our student housing subsidiary, Global Holdings, has developed into a leader in the Canadian market in the last several years, and we are ready to begin exploring alternatives to maximize the value of this asset, including the possibility of a listing it on North American stock exchange."

"In addition, over the past year, we have seen a shift in the global political environment in many Asian countries," continued Toby Chu. "This has led to an exodus of capital and a lack of available investment opportunities for real estate assets in Canada. We at CIBT believe we are well-positioned to offer a publically traded platform to many of these investors that are looking for a safe and reliable alternative method to invest in the Canadian student housing sector. Further, we believe the possibility of an additional exchange listing will provide many of these investors with a direct way of accessing this market."

The Company has not committed to any specific strategic alternative at this time, and there can be no assurance that the evaluation of strategic alternatives will result in any transaction or change in strategy.

About CIBT Education Group:

CIBT Education Group Inc. is one of the largest education, and student housing investment companies in Canada focused on the domestic and the global education market since 1994. CIBT owns business and language colleges, student-centric rental apartments, recruitment centres and corporate offices at 45 locations in Canada and abroad. Its education subsidiaries include Sprott Shaw College (established in 1903), Sprott Shaw Language College, Vancouver International College and CIBT School of Business. Through these schools, CIBT offers over 150 educational programs in healthcare, business management, e-commerce, hotel management and language training. The total annual enrollment for the group exceeds 12,000 students. CIBT owns Global Education City Holdings Inc. ("Global Holdings"), an investment holding and development company focused on education-related real estates such as student-centric rental apartments, hotels and education super-centres. Global Holdings, under the GEC® brand, provides accommodation service to 72 schools in Metro Vancouver, serving 1,500 students from 77 countries. The total portfolio and development budget under the GEC® brand exceeds C$1.4 billion. CIBT also owns Global Education Alliance ("GEA") and Irix Design Group ("Irix Design"). GEA recruits international students on behalf of many elite kindergartens, primary and secondary schools, colleges and universities in North America. Irix Design is a leading design and advertising company based in Vancouver, Canada. Visit us online and watch our corporate video at www.cibt.net.

Toby Chu
Chairman, President & CEO
CIBT Education Group, Inc.
Investor Relations Contact: 1-604-871-9909 extension 318 or | Email: info@cibt.net

FORWARD-LOOKING STATEMENTS

Some statements in this news release constitute forward-looking statements under applicable securities laws. Forward-looking statements are statements that are not historical facts. Forward-looking statements in this news release include, without limitation, those statements related to CIBT potentially spinning off Global Holdings as a separately listed entity on a recognized North American stock exchange while CIBT seeks strategic funding opportunities globally, the potential impact of such a transaction on shareholder value for shareholders of CIBT and CIBT's belief that it through Global Holdings is well-positioned to serve as a publicly traded platform for the Canadian student housing sector. The forward-looking statements are subject to various risks, uncertainties and other factors that could cause CIBT's actual results or achievements to differ materially from those expressed in or implied by forward-looking statements. Such risks, uncertainties and other factors are identified in CIBT's filings with the Canadian regulatory authorities and such filings are publicly available on SEDAR. Forward-looking statements are based on the beliefs, opinions and expectations of CIBT's management at the time they are made, and CIBT does not assume any obligation to update its forward-looking statements if those beliefs, opinions or expectations, or other circumstances should change, except as may be required by law.

SOURCE: CIBT Education Group Inc.

ReleaseID: 602839

Mr. Jordan to build commercial infrastructure in advance of potential Emergency Use Authorization of lenzilumab

BURLINGAME, CA / ACCESSWIRE / August 24, 2020 / Humanigen, Inc., (OTCQB:HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with lenzilumab, the company's proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, today announced the appointment of Edward P. Jordan, MBA, to Chief Commercial Officer, a new role that will report to Dr. Cameron Durrant, Chief Executive Officer of Humanigen, effective immediately.

Mr. Jordan has more than two decades of commercial operations experience at leading biotechnology and pharmaceutical companies, having launched over a dozen products and developed new therapeutic markets in the U.S. and abroad. He most recently served as Senior Vice President of DBV Technologies, where he built the North American commercial organization in preparation for the launch of a lifesaving pediatric biologic. Prior to DBV Technologies, Mr. Jordan held senior executive roles at AMAG Pharmaceuticals and Teva Pharmaceuticals. Mr. Jordan began his career at Schering-Plough, prior to the acquisition by Merck, and spent 18 years in sales and marketing leadership positions. Mr. Jordan received dual undergraduate degrees from The University of Rhode Island and an MBA from Southern New Hampshire University.

"We have been actively planning for launch as we develop our lead drug candidate, lenzilumab, for COVID-19. Ed's long tenure in senior commercial leadership roles, coupled with his track record of building cross-functional teams to achieve significant objectives in highly competitive markets, make him ideally suited to further strengthen Humanigen's commercialization plans," said Dr. Durrant. "Ed has demonstrated success in executive leadership, sales, marketing, managed markets, business development, international and domestic operations, finance, and joint venture partnerships, all of which will be valuable to Humanigen's strategic long-term domestic and global growth."

Mr. Jordan said, "I'm thrilled to join the Humanigen team at such a pivotal point as we work to bring lenzilumab to market during these difficult and unprecedented times. Having recently lost my father to a COVID-19 related condition, overseeing the potential commercialization of lenzilumab has special meaning to me and I'm steadfast in my commitment to get lenzilumab into the hands of professionals for the treatment of COVID-19 and other life-threatening conditions."

About Humanigen, Inc.
Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The company's immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit www.humanigen.com.

Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations surrounding the possibility that lenzilumab will receive Emergency Use Authorization for COVID-19 patients from the FDA in 2020, statements regarding the company's ability to commence commercialization activities subsequent to receipt of such authorization, and our statements regarding the intended purposes and effectiveness of lenzilumab and other technologies in our current pipeline. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to conduct the Phase III study and grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

CONTACT:
Media
Sean Leous
Westwicke, an ICR company
sean.leous@westwicke.com
646-866-4012

Investors
Victoria Meissner, MD
Westwicke, an ICR company
victoria.meissner@westwicke.com
646-677-1837

SOURCE: Humanigen, Inc.

ReleaseID: 602818

VANCOUVER, BC / ACCESSWIRE / August 24, 2020 /  Nanotech Security Corp. (TSXV:NTS)(OTCQX:NTSFF) ("Nanotech" or the "Company"), a leader in the development of secure and memorable nano-optic security features used in the government and banknote and brand protection markets, announces that President and CEO Troy Bullock will present the Company's investment thesis at the LD 500 investor conference on Tuesday, September 1, 2020 at 11:20am PDT/2:20pm EDT. Mr. Bullock and CFO Monika Russell will host investor meetings throughout the day.

LD 500 Virtual Conference for Investors September 1st through 4th.

Date: Tuesday, September 1, 2020

Time: 2:20 PM Eastern Time/11:20 AM Pacific Time

Webcast: https://www.webcaster4.com/Webcast/Page/2019/36124

To attend the LD 500 Virtual Investor Conference, register at https://ld-micro-conference.events.issuerdirect.com/. 1-on-1 investor meetings are available and will be scheduled and conducted via private, secure video conference through the conference event platform. Conference registration is required to book 1-on-1 investor meetings.

View Nanotech Security's LD Micro profile here: http://www.ldmicro.com/profile/NTS.V

About LD Micro

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.

The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone. For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

About Nanotech

With billions of security features in circulation, Nanotech's products include secure and memorable security labels, stripes, patches, and colour-shifting films for currency authentication and brand protection.

KolourOptik® is a patented technology that is exclusive to the government and banknote market and combines sub-wavelength nanostructures and microstructures to create modern overt security features with a unique and customizable visual effect. KolourOptik pure plasmonic colour pixels produce full colour, 3D depth, and movement used in security stripes and threads that are nearly impossible to replicate. At less than 5 microns thick, KolourOptik products seamlessly integrate into banknotes and other secure government documents.

LiveOptik™ is a patented technology that utilizes innovative nano-optics one tenth the size of traditional holographic structures to create next generation overt security features customized to our customers' unique requirements. LiveOptik delivers multi-colour, 3D depth, movement, and image switches for secure brand protection stripes, threads, and labels that are nearly impossible to replicate.

Additional information about Nanotech can be found at the Company's website www.nanosecurity.ca, the Canadian disclosure filings website www.sedar.com or the OTCMarkets disclosure filings website www.otcmarkets.com.

Nanotech Security Corp.:

Kelley Ryshak
info@nanosecurity.ca
+1.604.678.5775

Investor Relations:

Sean Peasgood
sean@SophicCapital.com
+1.647.699.9845

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Nanotech Security

ReleaseID: 602124

TORONTO, ON / ACCESSWIRE / August 24, 2020 / NextSource Materials Inc.'s (TSX:NEXT)(OTCQB:NSRCF) ("NextSource" or the "Company") Molo Graphite Project in Madagascar ranks as one of the largest-known and highest quality flake graphite deposits in the world. The Company continues to work towards advancing the development and construction of mining infrastructure at the Molo site.

In furtherance of the Company's efforts, NextSource is pleased to announce that Brett Whalen, CFA, has been appointed Chair of the Board effective immediately. Mr. Whalen takes over the role of Chair from Dean Comand, who served as the Company's chair since December 2019. Mr. Comand remains committed advancing to the Molo Graphite project and he will continue to serve as an independent director of NextSource.

Mr. Whalen, who joined the NextSource board on July 20th, 2020, brings over 20 years of investment banking and M&A expertise, spending over 16 of those years at Dundee Corporation ("Dundee Corp."). During his tenure at Dundee Corp., Mr. Whalen was directly involved in completing approximately $2 billion in M&A deals and helped raise over $10 billion dollars in capital for resource sector companies.

In addition to Mr. Whalen's capital markets experience, he brings significant general knowledge of the graphite, vanadium and the battery materials industries that will assist in securing the capital to build the Company's Molo mine and accelerate strategic plans for involvement in downstream value-added products such as graphite foils and battery anode material.

Craig Scherba, President and CEO commented, "I want to thank Dean for his service as Chair and welcome Brett to his expanded role with the Company. NextSource was fortunate to have had Brett's support while he was a portfolio manager at our largest institutional investor and we look forward to his capital markets expertise assisting at this pivotal time in the Company's development. NextSource remains focused on raising the necessary capital to construct Phase 1 of the Molo Graphite mine so the Company can realize production in 2021."

NextSource Implements Compensation Payment Deferral Plan and PSU Policy

The completion of a CAD$2,000,000 non-brokered private placement in July 2020, which received substantial support from existing shareholders, ensures the Company can operate well into 2021. To extend existing cash resources as the Company works to secure project specific financing, NextSource management has agreed to a plan to defer compensation payment by up to 30 percent and until total project financing has been secured.

In recognition of the deferral and to further incentivize management to expedite securing project financing upon the most favourable terms, the board proposes to implement a Performance Share Units ("PSU") plan for management. The PSU grant will be based on a Common Share value above the current market price and subject to shareholder approval. The PSU grants will vest and only be issued to management upon successfully achieving the full project financing milestone. The total number of Common Shares granted to each member of management as part of the PSU plan will be commensurate to the respective compensation amount being deferred. To further incentivize management to secure project financing in a timely manner, the number of PSUs granted will be reduced on certain deadline dates set out by the board if total project financing has not been achieved by that date. The plan provides that all PSUs will expire at the end of 18 months if total project financing has not been secured by this date.

Discussions with mine financiers continue in efforts to secure the US$24M required to fund Phase 1 production. Based on the most recent manufacturing lead time estimate, construction of the mine infrastructure is projected to take 9 months with commissioning of the Molo mine in month 10.

About NextSource Materials Inc.

NextSource Materials Inc. is a mine development company based in Toronto, Canada and is in the final development stage of its 100%-owned Molo Graphite Project in southern Madagascar. The Molo Graphite Project is a fully permitted, feasibility-stage project that ranks as one of the largest-known and highest quality flake graphite deposits in the world and is the only project with SuperFlake® graphite.

The Company will be utilizing an all-modular build approach to constructing the Molo mine and in two production phases. Phase 1 will produce 17,000 tonnes per annum ("tpa") over the first two years of production and Phase 2 producing a total of 45,000 tpa by year three. Offtakes are in place for 100% of Phase 1 production.

For further information contact: +1.416.364.4911

Brent Nykoliation, Senior Vice President, Corporate Development at brent@nextsourcematerials.com or Craig Scherba, President and CEO at craig@nextsourcematerials.com

Safe Harbour: This press release contains statements that may constitute "forward-looking statements" within the meaning of applicable Canadian and United States securities legislation. Readers are cautioned not to place undue reliance on such forward-looking statements. Forward-looking statements in this release relate to the results of the 2019 Feasibility Study, funding of the development of the Molo Project, expectation and timing of raising the mine capital, implementation and commencement of the build-out of the Molo Project, commencement of production at the Molo Project, commencement of procurement for mine infrastructure, the procurement of equipment to construct a mine, value engineering, any and all product test results, and the permit application. These are based on current expectations, estimates and assumptions that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by the Company and described in the forward-looking statements contained in this press release. No assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur or, if any of them do so, what benefits the Company will derive there from. The forward-looking statements contained in this news release are made as at the date of this news release and the Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws.

SOURCE: NextSource Materials Inc.

ReleaseID: 602940

FOOTHILL RANCH, CA / ACCESSWIRE / August 24, 2020 / BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced that President and CEO Todd Norbe and Executive Vice President and CFO John Beaver are scheduled to present to a live audience at the LD Micro 500 virtual investor conference on Thursday, September 3, 2020 at 1:40pm Pacific Time (4:40pm ET) and will be available for one-on-one meetings with investors throughout the day on September 1st thru 3rd.

The online presentation will be webcast live and available for replay at the investor relations section of BIOLASE's website at www.biolase.com. For additional information or to schedule a one-on-one meeting with BIOLASE, please contact your LD Micro representative.

The LD Micro 500 will take place September 1-4 and will feature some of the most prominent companies in the micro-cap world, with 500 companies expected to provide updates. Register here: https://ld-micro-conference.events.issuerdirect.com/

View BIOLASE's profile here: http://www.ldmicro.com/profile/BIOL. Profiles powered by LD Micro – News Compliments of Accesswire

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.

What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 261 patented and 52 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 41,200 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

For further information, please contact:

BIOLASE, Inc.
John R. Beaver, Executive Vice President, Chief Financial Officer and Chief Operating Officer
833-BIOLASE
jbeaver@biolase.com

or

EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
mpolyviou@evcgroup.com / tkehrli@evcgroup.com

SOURCE: BIOLASE, Inc. via LD Micro

ReleaseID: 602833